Payment overview · 2025
General Payments
$13,304.20
35 reported records · 15 companies
Healthcare provider profile · identity verified
Rogelio Machuca, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAS VEGAS, NV · NPI 1245492966
Verified facts
What the public records show
CMS Open Payments records show Rogelio Machuca, M.D. received $13,304.20 in general payments during 2025 across 35 reported records.
Hoffmann-La Roche Limited accounted for 88.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Hoffmann-La Roche Limited | Unresolved — no canonical attribution shown | $11,737.79 | 88.2% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $848.31 | 6.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.43 | 1.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $114.54 | 0.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.21 | 0.6% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $61.36 | 0.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.49 | 0.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.75 | 0.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.32 | 0.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.74 | 0.3% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $22.84 | 0.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.51 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.07 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.69 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.15 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $11,601.72 | 3 |
| Food and Beverage | $930.68 | 30 |
| Consulting Fee | $729.30 | 1 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $114.54 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.21 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.09 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $61.36 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.75 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.32 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 910 | 281 |
| Gabapentin | Gabapentin | 521 | 145 |
| Metformin Hcl | Metformin Hcl | 508 | 155 |
| Lisinopril | Lisinopril | 503 | 164 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 495 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 135 |
| Omeprazole | Omeprazole | 471 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 136 |
| Azithromycin | Azithromycin | 398 | 241 |
| Glimepiride | Glimepiride | 326 | 94 |
| Furosemide | Furosemide | 316 | 100 |
| Ibuprofen | Ibuprofen | 298 | 92 |
| Losartan Potassium | Losartan Potassium | 291 | 89 |
| Famotidine | Famotidine | 283 | 95 |
| Mirtazapine | Mirtazapine | 282 | 82 |
| Clopidogrel | Clopidogrel Bisulfate | 281 | 96 |
| Naproxen | Naproxen | 269 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 92 |
| Carvedilol | Carvedilol | 256 | 77 |
| Potassium Chloride | Potassium Chloride | 253 | 96 |
| Eliquis | Apixaban | 242 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 235 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 233 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 220 | 55 |
| Donepezil Hcl | Donepezil Hcl | 216 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 215 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 214 | 64 |
| Simvastatin | Simvastatin | 211 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 74 |
| Trazodone Hcl | Trazodone Hcl | 204 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 189 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 66 |
| Montelukast Sodium | Montelukast Sodium | 175 | 54 |
| Ammonium Lactate | Ammonium Lactate | 173 | 70 |
| Nystatin | Nystatin | 170 | 66 |
| Metformin Hcl Er | Metformin Hcl | 163 | 55 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 158 | 121 |
| Sertraline Hcl | Sertraline Hcl | 153 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 43 |
| Methocarbamol | Methocarbamol | 146 | 64 |
| Sucralfate | Sucralfate | 143 | 48 |
| Alendronate Sodium | Alendronate Sodium | 142 | 41 |
| Clonidine Hcl | Clonidine Hcl | 137 | 41 |
| Alprazolam | Alprazolam | 130 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 121 | 49 |
| Acyclovir | Acyclovir | 119 | 41 |
| Mounjaro | Tirzepatide | 118 | 28 |
| Risperidone | Risperidone | 118 | 20 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 117 | 62 |
| Meclizine Hcl | Meclizine Hcl | 116 | 49 |
| Memantine Hcl | Memantine Hcl | 112 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 106 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 106 | 84 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 99 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 96 | 32 |
| Silver Sulfadiazine | Silver Sulfadiazine | 94 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 30 |
| Ssd | Silver Sulfadiazine | 92 | 33 |
| Allopurinol | Allopurinol | 88 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 86 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 27 |
| Ozempic | Semaglutide | 83 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 26 |
| Levetiracetam | Levetiracetam | 77 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 20 |
| Spironolactone | Spironolactone | 71 | 20 |
| Lovastatin | Lovastatin | 70 | 21 |
| Clonazepam | Clonazepam | 68 | 17 |
| Ketoconazole | Ketoconazole | 67 | 23 |
| Lactulose | Lactulose | 66 | 35 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 66 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 57 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 29 |
| Bumetanide | Bumetanide | 65 | 19 |
| Finasteride | Finasteride | 64 | 24 |
| Meloxicam | Meloxicam | 63 | 25 |
| Erythromycin | Erythromycin Base | 62 | 26 |
| Amoxicillin | Amoxicillin | 61 | 47 |
| Midodrine Hcl | Midodrine Hcl | 61 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 13 |
| Cilostazol | Cilostazol | 58 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 58 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 29 |
| Metronidazole | Metronidazole | 56 | 38 |
| Hydrocortisone | Hydrocortisone | 52 | 24 |
| Linzess | Linaclotide | 52 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 38 |
| Divalproex Sodium | Divalproex Sodium | 49 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 13 |
| Jardiance | Empagliflozin | 48 | 19 |
| Timolol Maleate | Timolol Maleate | 48 | suppressed |
| Baclofen | Baclofen | 47 | 19 |
| Glipizide | Glipizide | 47 | 18 |
| Prednisone | Prednisone | 47 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 17 |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Farxiga | Dapagliflozin Propanediol | 44 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 16 |
| Topiramate | Topiramate | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 12 |
| Enalapril Maleate | Enalapril Maleate | 42 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 14 |
| Novolog Flexpen | Insulin Aspart | 39 | 15 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Atenolol | Atenolol | 38 | 17 |
| Loperamide | Loperamide Hcl | 38 | 14 |
| Ciclopirox | Ciclopirox | 37 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 32 |
| Fluconazole | Fluconazole | 37 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 12 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 17 |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 14 |
| Xarelto | Rivaroxaban | 29 | 13 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Captopril | Captopril | 25 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Permethrin | Permethrin | 25 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Constulose | Lactulose | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,304.20 · 35 records | Hoffmann-La Roche Limited | AFREZZA, AIRSUPRA, BREZTRI, CAPLYTA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, UNITHROID, WAYRILZ, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error